7 min read

Earnings Hints & Reports — November 16, 2026 — Midday Update — Last 24 Hours (Pacific Time)

XPeng surged 3% in premarket despite missing EPS, buoyed by strong revenue and bullish Q4 guidance, while the broader earnings landscape turned decisively bearish with double misses dominating small-caps in biotech, clean energy, and digital media.

Executive Summary

The latest 24-hour earnings window skews decisively bearish, with misses outnumbering beats by a wide margin across small- and micro-cap names. The most notable stock reaction came from XPeng, which rose more than 3% in premarket trading despite an EPS miss, driven by a strong revenue beat and a bullish Q4 delivery forecast. Chinese tech and consumer names dominated the macro narrative, while domestic small-caps — particularly in biotech, clean energy, and digital media — continued to struggle against analyst expectations.


Earnings Performance Breakdown

Note: Preview/outlook articles (AECOM, Viking, Powell Industries, Elbit Systems, Amer Sports, PagSeguro, Solaris, Tencent Music, Spire, Klarna, Miniso, Energizer, LuxExperience, Opera, Oaktree) are excluded from classification as they do not report actual results. Tyson Foods appears in two headlines (one miss, one beat framing) — consolidated as ⚪ Mixed. XPeng and Baidu each have two headlines — consolidated.

# Company Ticker EPS Revenue Classification
1 Rapid Micro Biosystems RPID Miss Miss 🔴 Double Miss
2 Phunware PHUN Miss Miss 🔴 Double Miss
3 HeartCore Enterprises HTCR Miss Miss 🔴 Double Miss
4 Data Storage DTST Miss Miss 🔴 Double Miss
5 Reading International B RDIB Beat Beat 🟢 Double Beat
6 Reading International A RDI Beat Beat 🟢 Double Beat
7 Jasper Therapeutics JSPR Miss Miss 🔴 Double Miss
8 Prelude PRLD Miss Miss 🔴 Double Miss
9 Scienture Holdings SCNX Miss Miss 🔴 Double Miss
10 Perion PERI Miss Miss 🔴 Double Miss
11 Veritone VERI Beat Miss ⚪ Mixed
12 Cycurion CYCU Beat Beat 🟢 Double Beat
13 T Stamp IDAI Match Miss ⚪ Mixed
14 Lanzatech Global LNZA Miss Miss 🔴 Double Miss
15 Outdoor Holding POWW Beat Beat 🟢 Double Beat
16 Tyson Foods TSN Miss/Beat* Miss ⚪ Mixed
17 Creative Realities CREX Miss Miss 🔴 Double Miss
18 Invivyd IVVD Miss Miss 🔴 Double Miss
19 Edible Garden EDBL Beat Beat 🟢 Double Beat
20 Ballard BLDP Miss Miss 🔴 Double Miss
21 Femasys FEMY Miss Miss 🔴 Double Miss
22 VistaGen Therapeutics VTGN Beat Miss ⚪ Mixed
23 Xtant Medical XTNT Miss Miss 🔴 Double Miss
24 Espey Mfg & Electronics ESP Miss Miss 🔴 Double Miss
25 Creative Media Community Trust CMCT Miss Beat ⚪ Mixed
26 Atlasclear Holdings ATCH Beat Miss ⚪ Mixed
27 Aramark US ARMK Miss Miss 🔴 Double Miss
28 TOYO Co TOYO Miss Miss 🔴 Double Miss
29 iQIYI ADR IQ Miss Miss 🔴 Double Miss
30 H World Group ADR HTHT Beat Beat 🟢 Double Beat
31 Xpeng XPEV Miss Beat ⚪ Mixed
32 Ke Holdings BEKE Beat Beat 🟢 Double Beat
33 Baidu ADR BIDU Miss Beat ⚪ Mixed
34 Idaho Strategic Resources IDR Miss Miss 🔴 Double Miss
35 22nd Century XXII Beat Miss ⚪ Mixed
36 Toyo Tire — N/A (guidance cut) — 🔴 Double Miss
37 Applied Nutrition — N/A (dividend halt) — 🔴 Double Miss
38 Legal & General — Miss (pension volumes) Miss 🔴 Double Miss
39 Ascent Solar ASTI Miss Miss 🔴 Double Miss
40 Sunshine Biopharma SBFM Miss Beat ⚪ Mixed

Summary Count

Category Count % of Classified
🟢 Double Beat 7 17.5%
⚪ Mixed 11 27.5%
🔴 Double Miss 22 55.0%

Tyson Foods headlines present conflicting framing — one headline says "missed by $0.14," another says "beats analyst expectations." Classified as ⚪ Mixed pending full reconciliation.


Notable Earnings Reports

🔴 Jasper Therapeutics (JSPR) — Major Miss

  • EPS of -$10.19, missing estimates by $7.79; revenue also fell short.
  • A massive per-share shortfall for a clinical-stage biotech — suggests elevated cash burn and/or one-time charges well beyond what analysts modeled.

🔴 Lanzatech Global (LNZA) — Major Miss

  • EPS of -$13.60, missing by $12.79; revenue also fell short.
  • One of the largest absolute EPS misses in this batch; the carbon-capture/biotech firm continues to burn cash at a pace that far exceeded consensus.

🟢 Ke Holdings (BEKE) — Major Beat

  • EPS of ¥15.76, beating by ¥14.04; revenue also topped estimates.
  • A standout result from China's real estate platform, suggesting a meaningful recovery in Chinese property transaction volumes.

🟢 H World Group ADR (HTHT) — Double Beat

  • EPS of ¥6.23, beating by ¥0.82; revenue also topped estimates.
  • China's hotel sector showing resilience, with H World delivering on both top and bottom lines.

⚪ XPeng (XPEV) — Mixed but Market-Positive

  • EPS of ¥-0.91, missing by ¥0.46; revenue topped estimates.
  • Shares rose more than 3% in premarket on a strong revenue beat and a bullish Q4 delivery forecast — the market is clearly prioritizing volume growth over near-term profitability.

⚪ Baidu ADR (BIDU) — Mixed

  • EPS of ¥6.78, missing by ¥1.38; revenue topped estimates.
  • A 22% slump in core online advertising dragged on profits even as AI cloud revenue surged — a tale of two businesses.

🔴 Scienture Holdings (SCNX) — Large Miss

  • EPS of -$3.76, missing by $1.76; revenue also fell short.
  • A significant shortfall for a small-cap pharma, nearly doubling the expected loss per share.

⚪ Tyson Foods (TSN) — Mixed

  • EPS of $0.61 reported; one headline frames it as a $0.14 miss vs. the $0.75 estimate, while another frames it as a beat citing multiprotein model strength.
  • The conflicting framing likely reflects a difference between GAAP and adjusted figures; the multiprotein diversification narrative remains the key strategic story.

🔴 Phunware (PHUN) — Large Miss

  • EPS of -$0.34, missing by $0.23 vs. an estimate of -$0.11; revenue also fell short.
  • A significant proportional miss for the mobile software firm, with losses running more than three times the expected level.

🟢 Cycurion (CYCU) — Large Beat

  • EPS of -$1.03, beating by $3.29 vs. an estimate of -$4.32; revenue also topped estimates.
  • A dramatic positive surprise for the cybersecurity firm, cutting expected losses by more than 75%.

Sector Analysis

🔴 Biotech / Pharma — Broad Weakness
Multiple clinical-stage names missed badly: Jasper Therapeutics (-$7.79 EPS miss), Scienture Holdings (-$1.76), Prelude (-$0.12), Femasys (-$0.06), Invivyd (-$0.01), and Ascent Solar (solar-adjacent). Cash burn is running ahead of estimates across the board, a consistent theme for development-stage companies.

🔴 Clean Energy / Sustainability — Struggling
Ballard (hydrogen fuel cells), Lanzatech Global (carbon capture), and Ascent Solar all missed on both EPS and revenue. The sector continues to face a difficult path to profitability despite long-term tailwinds.

🟢 Chinese Consumer & Tech — Selective Strength
A split picture: Ke Holdings and H World Group delivered strong double beats, and XPeng's revenue beat drove a positive stock reaction. However, Baidu missed on EPS due to ad weakness, and iQIYI missed on both lines. Chinese real estate recovery and hotel demand appear stronger than digital advertising.

⚪ Food & Beverage — Mixed
Tyson Foods delivered a muddled result depending on which metric you use, with the multiprotein model cited as a positive structural driver even as headline numbers disappointed.

🔴 Digital Media / AdTech — Weak
Perion (adtech) missed on both lines. iQIYI (streaming) missed. Veritone (AI media) beat on EPS but missed on revenue. The digital advertising environment remains challenging.

🔴 Small-Cap Industrials & Services — Broadly Weak
Aramark, Espey Mfg, TOYO Co, Creative Realities, and Xtant Medical all missed on both lines — a broad-based softness in smaller industrial and services names.


Biggest Movers

Company Move Direction Trigger
XPeng (XPEV) +3%+ 🟢 Up Revenue beat + strong Q4 delivery forecast
Legal & General -2%+ 🔴 Down Q3 pension risk transfer volumes missed estimates
Applied Nutrition -4%+ 🔴 Down Annual dividend halted until at least FY28

No other specific percentage stock moves were provided in the available headlines. Surprise magnitude leaders: Ke Holdings (+¥14.04 beat), Lanzatech Global (-$12.79 miss), Jasper Therapeutics (-$7.79 miss), Cycurion (+$3.29 beat), Edible Garden (+$4.70 beat).


Earnings Sentiment

Net Sentiment: 🔴 Bearish
Misses account for 55% of classified results, with mixed outcomes adding another 27.5% — leaving only 17.5% as clean double beats.

The beat rate is notably weak even by small-cap standards, where volatile EPS estimates typically inflate beat rates. Guidance trends are also concerning: Toyo Tire cut its full-year guidance citing weaker sales, and Applied Nutrition suspended its dividend through at least FY28 — both signals of deteriorating forward confidence. Stock reactions are skewed negative, with Legal & General and Applied Nutrition both falling on their reports, while XPeng stands out as the rare positive catalyst, rewarded more for its delivery outlook than its actual EPS.


Market Implications

The sheer breadth of misses across small- and micro-cap names — spanning biotech, clean energy, digital media, and industrials — suggests that cost pressures and revenue shortfalls are not isolated to one sector. For investors, this reinforces a selective, quality-over-quantity approach: the companies being rewarded (XPeng, Ke Holdings, H World) are those demonstrating tangible volume growth or market share gains, not just cost management.

The China story is nuanced. Real estate platform Ke Holdings and hotel operator H World both beat convincingly, suggesting that China's domestic consumer recovery has legs in property transactions and travel. But Baidu's ad revenue slump and iQIYI's miss highlight that digital advertising in China remains under structural pressure — a divergence worth watching as more Chinese ADRs report.

Forward guidance is the wildcard. With Toyo Tire cutting full-year guidance and Applied Nutrition halting its dividend, investors should watch Tuesday's slate — including Viking Holdings, Elbit Systems, Amer Sports, Klarna, Energizer, and Tencent Music — for any guidance revisions that could shift sector sentiment more broadly.


Key Takeaways

  • 🔴 Jasper Therapeutics (JSPR) — A $7.79 EPS miss signals cash burn far exceeding model assumptions; watch liquidity runway closely.
  • 🔴 Lanzatech Global (LNZA) — A $12.79 EPS miss is one of the largest absolute misses in this batch; clean-tech profitability timelines remain elusive.
  • 🟢 Ke Holdings (BEKE) — A ¥14.04 EPS beat is the biggest positive surprise; China's property transaction recovery may be gaining real momentum.
  • 🟢 XPeng (XPEV) — Despite an EPS miss, +3% premarket move shows the market is valuing delivery volume and Q4 trajectory over near-term profitability.
  • ⚪ Baidu (BIDU) — AI cloud is growing but can't yet offset a 22% ad revenue collapse; the transition story is real but painful.
  • 🟢 H World Group (HTHT) — Double beat confirms Chinese travel/hospitality demand remains robust heading into year-end.
  • 🔴 Tyson Foods (TSN) — Conflicting headline framing (miss vs. beat) likely reflects GAAP vs. adjusted figures; multiprotein diversification is the long-term thesis to watch.
  • 🔴 Phunware (PHUN) — Losses running 3x the expected level; revenue also missed — a difficult quarter for the mobile software firm.
  • 🟢 Cycurion (CYCU) — Cut expected losses by more than 75% vs. estimates; a rare bright spot in cybersecurity small-caps.
  • 🔴 Applied Nutrition — Dividend halted until at least FY28 and shares fell 4%+; a clear signal of near-term cash flow stress.
  • 🔴 Legal & General — Pension risk transfer volumes missed, shares fell 2%+; UK insurance sector faces demand headwinds.
  • 🔴 Toyo Tire — Full-year guidance cut on weaker sales; a forward-looking warning for the auto parts supply chain.
  • 🔴 Clean energy sector (BLDP, LNZA, ASTI) — Three clean-energy names all missed on both lines; the path to profitability remains distant across the space.
  • 🔴 Aramark (ARMK) — Missed on both EPS and revenue in Q4; food services demand softness worth monitoring given its broad enterprise customer base.
  • ⚪ Tuesday's slate is loaded — Viking, Klarna, Elbit Systems, Amer Sports, Energizer, and Tencent Music all report; guidance commentary will be the key market signal.

Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

👉 This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/